Somewhat Favorable News Coverage Somewhat Unlikely to Affect Evolent Health (EVH) Share Price

Headlines about Evolent Health (NYSE:EVH) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evolent Health earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news coverage about the technology company an impact score of 45.4355452886101 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

Shares of EVH stock opened at $15.70 on Monday. The company has a market cap of $1,215.76, a P/E ratio of -22.43 and a beta of 1.07. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.85 and a current ratio of 2.85. Evolent Health has a 52-week low of $10.30 and a 52-week high of $27.50.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, February 27th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The company had revenue of $113.97 million for the quarter, compared to analyst estimates of $111.09 million. Evolent Health had a negative net margin of 14.05% and a negative return on equity of 3.51%. sell-side analysts anticipate that Evolent Health will post -0.34 earnings per share for the current fiscal year.

EVH has been the topic of a number of research reports. Canaccord Genuity reduced their target price on shares of Evolent Health from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Jefferies Group set a $22.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research report on Tuesday, February 13th. Citigroup initiated coverage on shares of Evolent Health in a research report on Thursday, January 4th. They set a “buy” rating on the stock. Wells Fargo reduced their target price on shares of Evolent Health from $27.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. Finally, Zacks Investment Research lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Thursday, March 8th. Three investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company. Evolent Health has an average rating of “Buy” and a consensus target price of $25.33.

In related news, Director Unitedhealth Group Inc sold 3,040,000 shares of Evolent Health stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $13.70, for a total transaction of $41,648,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with's FREE daily email newsletter.

Leave a Reply